Izotropic Canada Stock Price, News & Analysis

Izotropic Corporation (OTCQB: IZOZF) has secured exclusive U.S. patent rights for computer-aided diagnosis (CADx) with breast CT technology through a global license agreement with the University of California. The company's flagship device, IzoView Breast CT Imaging System, is being developed as a 3D breast imaging solution positioned between Digital Breast Tomosynthesis (DBT) and MRI.

While IzoView will initially launch without CADx functionality, it will include a proprietary machine-learning image reconstruction algorithm that optimizes images while maintaining low radiation doses. The CADx feature will be integrated post-market launch as a software upgrade, potentially serving as an incentive for early adopters and creating future revenue opportunities.

Izotropic Corporation (OTCQB: IZOZF) has announced a significant AI breakthrough in breast CT imaging with its proprietary machine-learning reconstruction algorithm integration into the IzoView Breast CT Imaging System. The algorithm, developed in collaboration with Johns Hopkins University School of Medicine, enhances image quality while maintaining low radiation doses.

The company's innovative AI solution addresses key limitations of existing CT denoising methods like Model-Based Iterative Reconstruction (MBIR) and Deep Machine-Learning Reconstruction (DMLR). The algorithm works on raw X-ray data before reconstruction, enabling faster processing and consistent image optimization at low radiation doses.

Trained on 15 years of specialized breast CT data and protected as a trade secret, the technology provides Izotropic with a significant competitive advantage in the breast CT imaging market.

Izotropic Corporation (OTCQB: IZOZF) has launched BreastCT.com, a comprehensive educational platform focused on breast CT technology and the company's IzoView Breast CT Imaging System. The website aims to educate about dedicated breast CT technology, particularly highlighting its potential in addressing breast cancer detection challenges for the 50% of women with dense breast tissue.

With IzoView's engineering phase now complete, the platform will evolve through clinical studies, regulatory phases, and commercial launch preparations. The site also contextualizes Izotropic's position by featuring successful public companies that have established new imaging categories, helping build market recognition ahead of future milestones.

Izotropic Corporation (OTCQB: IZOZF), a medical device company focused on breast cancer imaging technology, has unveiled its new corporate website and brand identity. The redesigned website, izocorp.com, showcases the company's refined positioning and modern visual identity, emphasizing its focus on patients, clinicians, and healthcare stakeholders.

The company introduced two new taglines: "Advanced Imaging. Accessible Care." for corporate communications, and "Engineered for Today's Challenges and Tomorrow's Care Models" for their flagship IzoView Breast CT Imaging System. The updated website features enhanced navigation, new presentations, and video materials highlighting Izotropic's value proposition and strategic direction toward commercialization.

Izotropic Corporation (OTCQB: IZOZF) has launched a new podcast series focused on breast imaging innovation, with its first episode titled "Beyond the Mammogram: Rethinking the Future of Breast Imaging." The podcast, available in seven languages including English, aims to educate global audiences about advancements in breast cancer detection technology.

The premiere episode discusses the limitations of current breast imaging methods, particularly for the approximately 50% of women with dense breast tissue. With breast cancer projected to affect over 315,000 women in the U.S. in 2025, the podcast highlights the need for improved detection technologies, including Izotropic's flagship product IzoView, a dedicated Breast CT Imaging System.

Izotropic (OTCQB: IZOZF) positions its IzoView Breast CT Imaging System to capitalize on the expanding global breast imaging market, projected to reach $8.69 billion by 2030 (CAGR 8.25%). The company's innovative technology addresses critical market needs in dense breast imaging, where approximately 50% of women require enhanced screening solutions.

IzoView, priced at $500,000, offers significant cost advantages compared to competitors priced at $1.2-1.5 million. The system delivers true 3D imaging without breast compression, featuring 100x greater spatial resolution than MRI and a rapid 10-second exam time. The platform supports 14 potential future indications across screening, diagnosis, monitoring, planning, and personalized medicine, with patent protection extending into the 2040s.

The technology aligns with key market drivers including AI integration, personalized screening protocols, and improved patient experience, positioning IzoView in the fastest-growing "Other" category of breast imaging modalities with a CAGR of 11.15%.

Izotropic Corporation (OTCQB: IZOZF) has positioned its flagship device, IzoView Breast CT Imaging System, as a disruptive technology in the breast imaging market. The device, targeting a $500,000 price point, bridges the gap between Digital Breast Tomosynthesis (DBT) and MRI technologies.

IzoView offers true 3D imaging without breast compression and provides 100x greater spatial resolution compared to MRI. The device is entering the global breast imaging market, projected to grow from $5.4 billion in 2024 to $8.69 billion by 2030 at an 8.25% CAGR.

The system's initial indication targets adjunct screening for dense breast tissue patients, with 14 potential future indications across screening, diagnosis, monitoring, planning, and personalized medicine. IzoView's modular design enables software upgrades without core system replacement, creating a recurring revenue model with patent protections extending into the 2040s.

Izotropic (OTCQB: IZOZF) has announced strategic awareness initiatives ahead of the commercialization of its IzoView Breast CT Imaging System. The company is launching three key platforms: a comprehensive awareness campaign, a new podcast series, and a dedicated website at breastct.com.

The awareness campaign will focus on highlighting IzoView's proprietary features, including patented hardware innovations, trade-secret software elements, and next-generation AI integrations. The podcast series will provide commentary on corporate updates, clinical milestones, and regulatory progress. The breastct.com website will serve as an educational resource for patients, clinicians, and advocates regarding breast CT technology.

Izotropic Corporation, a medical device company focused on breast cancer imaging technology, has engaged Evolux Capital for marketing services. The six-month contract, ending December 11, 2025, includes social media advertising, communications strategy, and brand development. As compensation, Evolux will receive 200,000 Restricted Share Units (RSUs) before service commencement. Additionally, the company issued 60,000 RSUs to consultants, bringing the total RSU issuance to 260,000 units under their Long Term Incentive Plan, all vesting immediately.